Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Genet ; 81(6): 590-4, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21797849

ABSTRACT

Noonan and Cardio-facio-cutaneous (CFC) syndromes are characterized by typical dysmorphic features, cardiac defects, short stature, variable ectodermal anomalies, and intellectual disability. Both belong to the Ras/mitogen-activated protein kinase pathway group of disorders and clinical features overlap other related conditions, notably LEOPARD and Costello syndromes. KRAS mutations account for about 2% of reported Noonan and <5% of reported CFC cases. The mutation spectrum includes recurrent missense changes clustering in particular domains of the KRAS protein and conferring gain-of-function. We report three patients from two unrelated families with novel missense KRAS mutations, p.K147E and p.Y71H. Both mutations affect a residue which is highly conserved in KRAS and other RAS isoforms. One of the families includes a mother and son pair who represent the first report of a vertically transmitted KRAS mutation. In addition, the mother and son pair had peripheral neuropathy, complicated by Charcot arthropathy in the mother. An unusual phenotypic effect of the specific KRAS mutation or a coincidence of two independent disorders may be considered. KRAS mutation-associated phenotypes appear to be subject to considerable clinical heterogeneity. All three cases highlight the challenges of clinical assessment in KRAS mutation-positive patients, and the utility of molecular testing as an adjunct to diagnosis.


Subject(s)
Germ-Line Mutation , Phenotype , Proto-Oncogene Proteins/genetics , ras Proteins/genetics , Arthropathy, Neurogenic/complications , Arthropathy, Neurogenic/genetics , Child, Preschool , Diagnosis, Differential , Ectodermal Dysplasia/complications , Ectodermal Dysplasia/genetics , Facies , Failure to Thrive/complications , Failure to Thrive/genetics , Female , Heart Defects, Congenital/complications , Heart Defects, Congenital/genetics , Humans , Male , Mitogen-Activated Protein Kinases/genetics , Noonan Syndrome/genetics , Pedigree , Peripheral Nervous System Diseases/complications , Peripheral Nervous System Diseases/genetics , Proto-Oncogene Proteins p21(ras)
2.
Oncogene ; 29(46): 6184-92, 2010 Nov 18.
Article in English | MEDLINE | ID: mdl-20729911

ABSTRACT

Microtubule-interfering cancer drugs such as paclitaxel (PTX) often cause chemoresistance and severe side effects, including neurotoxicity. To explore potentially novel antineoplastic molecular targets, we investigated the cellular response of breast carcinoma cells to short hairpin(sh)RNA-mediated depletion of the centrosomal protein transforming acidic coiled coil (TACC) 3, an Aurora A kinase target expressed during mitosis. Unlike PTX, knockdown of TACC3 did not trigger a cell death response, but instead resulted in a progressive loss of the pro-apoptotic Bcl-2 protein Bim that links microtubule integrity to spindle poison-induced cell death. Interestingly, TACC3-depleted cells arrested in G1 through a cellular senescence program characterized by the upregulation of nuclear p21(WAF), downregulation of the retinoblastoma protein and extracellular signal-regulated kinase 1/2, formation of HP1γ (phospho-Ser83)-positive senescence-associated heterochromatic foci and increased senescence-associated ß-galactosidase activity. Remarkably, the onset of senescence following TACC3 knockdown was strongly accelerated in the presence of non-toxic PTX concentrations. Thus, we conclude that mitotic spindle stress is a major trigger of premature senescence and propose that the combined targeting of the centrosomal Aurora A-TACC3 axis together with drugs interfering with microtubule dynamics may efficiently improve the chemosensitivity of cancer cells.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Cellular Senescence/drug effects , Microtubule-Associated Proteins/physiology , Paclitaxel/pharmacology , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p21/physiology , Doxorubicin/pharmacology , Extracellular Signal-Regulated MAP Kinases/physiology , Humans , Microtubules/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...